Science Explorer Back to mapMap

Most cited papers from IMMUNOe Research Center

What are the most cited papers from IMMUNOe Research Center?

The most cited paper from IMMUNOe Research Center is "Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial" (Richard C. Dodel et al., 2013), with 186 citations. Next come "Mast cells, brain inflammation and autism" (138) and "Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency" (131).

Showing 50 of 81 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Richard C. Dodel et al. · The Lancet Neurology Open access 30 Jan 2013 186
2 Mast cells, brain inflammation and autism Theoharis Constantin Theoharides, Julia Marie Stewart, Smaro Panagiotidou et al. · European Journal of Pharmacology 3 May 2015 138
3 Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency John B. Hagan, Mary Beth Fasano, Sheldon L. Spector et al. · Journal of Clinical Immunology Open access 7 May 2010 131
4 Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033 Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof et al. · Neurology Neuroimmunology & Neuroinflammation Open access Aug 2014 125
5 Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America Daniel Suez, Mark R. Stein, Sudhir Gupta et al. · Journal of Clinical Immunology Open access 31 Aug 2016 65
6 Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency Richard L. Wasserman, Isaac Melamed, Robert P. Nelson et al. · Clinical Pharmacokinetics 10 May 2011 65
7 Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms Craig D. Shimasaki, Richard E. Frye, Rosario Rich Trifiletti et al. · Journal of Neuroimmunology Open access 14 Dec 2019 60
8 Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Clinical Immunology Open access 25 May 2016 50
9 A pilot study of high‐dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation Isaac Melamed, Melinda Heffron, Alessandro Testori et al. · Autism Research 10 Feb 2018 45
10 Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability Richard L. Wasserman, Isaac Melamed, Lisa J. Kobrynski et al. · Immunotherapy Open access 28 Jul 2016 40
11 Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome Isaac Melamed, Roger H. Kobayashi, Maeve O’Connor et al. · Journal of Child and Adolescent Psychopharmacology Open access 18 Feb 2021 31
12 Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies Ann M. Ranger, Soma S. Ray, Suzanne T. Szak et al. · Neurology Neuroimmunology & Neuroinflammation Open access 16 Dec 2017 31
13 Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease Richard L. Wasserman, William R. Lumry, James B. Harris et al. · Journal of Clinical Immunology Open access 20 Jun 2016 30
14 Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed et al. · Frontiers in Immunology Open access 4 Feb 2019 22
15 Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study Isaac Melamed, Michael Borte, Laurenz Trawnicek et al. · European Journal of Pharmaceutical Sciences Open access 6 Mar 2018 20
16 Attention Deficit Disorder and Allergic Rhinitis: Are They Related? Isaac Reuven Melamed, Melinda Heffron · Journal of Immunology Research Open access 2016 20
17 Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study Michael Borte, Isaac Melamed, Grażyna Pulka et al. · Journal of Clinical Immunology Open access 28 Jul 2017 16
18 Subcutaneous Immunoglobulins: Product Characteristics and Their Role in Primary Immunodeficiency Disease Isaac Melamed, Alessandro Testori, Zvi Spirer · International Reviews of Immunology 7 Dec 2012 16
19 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Clinical Immunology Open access 18 Mar 2017 15
20 Efficacy and safety of Gammaplex® 5% in children and adolescents with primary immunodeficiency diseases Isaac Melamed, Sudhir Gupta, M Stratford Bobbitt et al. · Clinical & Experimental Immunology Open access 23 Dec 2015 14
21 IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures Isaac Melamed, Shamma Shakila Rahman, Heather Pein et al. · Frontiers in Immunology Open access 3 Oct 2024 13
22 Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens Sudhir Gupta, James DeAngelo, Isaac Melamed et al. · Journal of Clinical Immunology Open access 9 May 2023 11
23 Angiographic Evaluation of Cranial Venous Outflow Patterns in Patients With and Without Idiopathic Intracranial Hypertension Mithun G. Sattur, Matthew Robert Amans, Kyle Michael Fargen et al. · Operative Neurosurgery 26 Sep 2022 11
24 Intravenous Immunoglobulin 10% in Children with Primary Immunodeficiency Diseases Hans D. Ochs, Isaac Melamed, Michael Borte et al. · Immunotherapy Open access 8 Aug 2018 11
25 On the Use of Ratio Statistics for the Evaluation of Operational Cloud Seeding Programs Bernard A. Silverman · The Journal of Weather Modification Open access Apr 2007 11
26 Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies Roger H. Kobayashi, Jiří Litzman, Isaac Melamed et al. · Clinical & Experimental Immunology Open access 8 Oct 2022 10
27 Canadian Society of Allergy and Clinical Immunology annual scientific meeting 2016 and the Canadian Healthy Infant Longitudinal Development Study Investigators et al. · Allergy Asthma and Clinical Immunology Open access228 authors 7 Apr 2017 8
28 Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease Jennifer R. Heimall, Junliang Chen, Joseph A. Church et al. · Journal of Clinical Immunology 24 Jun 2016 7
29 Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension Henriette Farkas et al. · The Journal of Allergy and Clinical Immunology In Practice Open access 29 Aug 2025 6
30 Neurologic manifestations of hereditary angioedema Alessandro Testori, Isaac Melamed · Annals of Allergy Asthma & Immunology 19 Dec 2016 6
31 Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs) Isaac Reuven Melamed, Richard L. Wasserman, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology 23 Jan 2014 6
32 Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ® [Octanorm]) Roger H. Kobayashi, J. Fernando Mandujano, Syed M. Rehman et al. · Immunotherapy Open access 6 May 2021 5
33 A new subset of common variable immune deficiency characterized by reduced C1 esterase inhibitor levels Isaac Melamed, Melinda Heffron, Sean P. McGee et al. · Annals of Allergy Asthma & Immunology 26 Jun 2015 5
34 The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies Isaac Reuven Melamed, Lacey B. Robinson, Melinda Heffron · Journal of Allergy and Clinical Immunology Feb 2010 4
35 An Analysis of Safety and Tolerability Data on 10%, 16%, and 20% Formulations of Subcutaneous Immunoglobulin (IGSC) Isaac Reuven Melamed, A. C. McDonald, ANN G. NEFF et al. · Journal of Allergy and Clinical Immunology Feb 2011 4
36 BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children Gergely Kriván, Michael Borte, Pere Soler‐Palacín et al. · Journal of Clinical Immunology Open access 16 Nov 2022 3
37 Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study Isaac Melamed, Holly Miranda, Melinda Heffron et al. · Frontiers in Immunology Open access 2 Mar 2021 3
38 Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency J.J. Hagan, M.B. Fasano, Sheldon L. Spector et al. · Journal of Allergy and Clinical Immunology Feb 2010 3
39 Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD) Richard L. Wasserman, Isaac Reuven Melamed, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology Feb 2012 3
40 Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S Jonathan A. Bernstein et al. · Clinical and Translational Allergy Open access Nov 2025 2
41 Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study Isaac Melamed, Caley Buckley, Mary Ellen Bayko et al. · Frontiers in Neurology Open access 6 Nov 2025 2
42 The “Perfect Cytokine Storm” of COVID-19 Alessandro Testori · Mayo Clinic Proceedings Open access 29 May 2020 2
43 Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD) Isaac Reuven Melamed, Richard L. Wasserman, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology Feb 2012 2
44 Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI) Richard L. Wasserman, Mark R. Stein, Isaac Melamed et al. · Journal of Allergy and Clinical Immunology Feb 2015 2
45 Building Your Practice with Fillers Ron D. Shippert · The American Journal of Cosmetic Surgery Jun 2007 1
46 Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies Mark R. Stein, Richard L. Wasserman, Isaac Reuven Melamed et al. · Journal of Allergy and Clinical Immunology Feb 2016 1
47 Pharmacokinetics of RI-002, an Investigational Igiv Preparation James J. Mond, Charlotte Cunningham‐Rundles, Ann Regina Falsey et al. · Journal of Allergy and Clinical Immunology Open access Feb 2015 1
48 Sa.46. Autism as a Neuro-Immune Disease-the Benefit Effect of IVIG Isaac Melamed, Angela McDonald, Mónica González-Magaldi · Clinical Immunology 2006 1
49 Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD) Heinz Leibl, Richard L. Wasserman, Isaac Melamed et al. · Journal of Allergy and Clinical Immunology Open access Feb 2011 1
50 Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD) Mark R. Stein, Richard L. Wasserman, Isaac Reuven Melamed et al. · Journal of Allergy and Clinical Immunology Open access Feb 2012 1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.